PT  - JOURNAL ARTICLE
AU  - Duncan, Polly
AU  - Mears, Ruth
AU  - Begier, Elizabeth
AU  - Rouhbakhsh Halvaei, Sanaz
AU  - Southern, Jo
AU  - Porter, Siân Bodfel
AU  - Hubler, Robin
AU  - Oben, Glenda
AU  - Qian, George
AU  - Lahuerta, Maria
AU  - Davis, Tim
AU  - Campling, James
AU  - Dawson, Shoba
AU  - Christensen, Hannah
AU  - Oliver, Jennifer
AU  - Morales-Aza, Begonia
AU  - Pan, Kaijie
AU  - Gray, Sharon
AU  - Hyams, Catherine
AU  - Danon, Leon
AU  - Gessner, Bradford D
AU  - Finn, Adam
AU  - Hay, Alastair D
AU - AvonCAP GP2 research group
TI  - Estimating the burden of vaccine-preventable lower respiratory tract disease in UK primary care: protocol for a prospective surveillance study (AvonCAP GP2)
AID  - 10.3399/BJGPO.2024.0129
DP  - 2024 Dec 01
TA  - BJGP Open
PG  - BJGPO.2024.0129
VI  - 8
IP  - 4
4099  - http://bjgpopen.org/content/8/4/BJGPO.2024.0129.short
4100  - http://bjgpopen.org/content/8/4/BJGPO.2024.0129.full
SO  - BJGP Open2024 Dec 01; 8
AB  - Background The true burden of acute lower respiratory tract disease (aLRTD; includes acute lower respiratory tract infection [aLRTI] and presumed non-infective exacerbations of chronic lung disease and heart failure) among adults presenting to primary care, and the proportion that are potentially vaccine preventable is unknown.Aim To describe aLRTD incidence in adults presenting to primary care; estimate proportions caused by respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Streptococcus pneumoniae (SP); and investigate disease burden from patient and NHS perspectives.Design & setting Primary care prospective cohort study conducted in six representative general practices (total ∼86 000 registered adults) in Bristol, UK.Method Adults (aged ≥18 years) registered at participating general practices and presenting to primary care (in-hours or out-of-hours) or emergency department (if not admitted) with aLRTD will be eligible. They will be identified by real-time primary care record searches. Researchers will screen electronic GP records, including free text, contact patients to assess eligibility, and offer enrolment in a surveillance study and an enhanced diagnostic study (urine, saliva, and respiratory samples; physical examination; and symptom diaries). Data will be collected for all aLRTD episodes, with patients assigned to one of three arms: surveillance; embedded diagnostic; and descriptive dataset. Outcome measures will include clinical and pathogen-defined aLRTD incidence rates, symptom severity and duration, NHS contacts and costs, health-related quality-of-life changes, and mortality (≤30 days post-identification).Conclusion This comprehensive surveillance study of adults presenting to primary care with aLRTD, with embedded detailed data and sample collection, will provide an accurate assessment of aLRTD burden due to vaccine-preventable infections.